2m 2m 2m 2m 2m 2m 2m
Cytosorbents (CTSO)
NASDAQ
$0.51+$0.03 (+5.63%)
Price as of Jun 03, 2026 7:29 PM EDT- $30.8MMarket Cap
- -52.00%1-Year Change
- Medical DevicesIndustry
Cytosorbents (CTSO)
$0.51+$0.03 (+5.63%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 37.1M +4.13% | 35.6M -2.08% | 36.3M +4.79% | 34.7M -19.64% | |
Cost of Revenue | 10.6M +0.99% | 10.5M -25.00% | 14.0M +0.01% | 14.0M +26.33% | |
Gross Profit | 26.5M +5.43% | 25.1M +12.21% | 22.4M +8.00% | 20.7M -35.45% | |
Sales and Marketing Expense | 35.6M +1.86% | 35.0M +4.15% | 33.6M -2.01% | 34.3M -4.09% | |
Research and Development Expense | -3.4M -69.97% | -11.2M -28.50% | -15.7M +4.03% | -15.1M -7.70% | |
Depreciation and Amortization Expense | 1.2M -21.41% | 1.6M +7.36% | 1.5M +65.69% | 882,621 +20.65% | |
Total Operating Expenses | 41.2M -1.60% | 41.9M -21.81% | 53.6M +2.58% | 52.3M -4.75% | |
Operating Profit | -14.7M -12.13% | -16.8M -46.21% | -31.2M -0.99% | -31.5M +38.59% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -2.6M +86.69% | -1.4M +786.11% | -157,891 N/A | N/A N/A | |
Interest Income and Expense and Net | -2.6M +86.69% | -1.4M +786.11% | -157,891 N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | 6.2M +209.36% | -5.6M -397.85% | 1.9M +179.22% | -2.4M -6.53% | |
Income before Taxes | -8.6M -61.63% | -22.4M -23.57% | -29.3M -13.52% | -33.9M +34.04% | |
Income Taxes | -401,000 -76.28% | -1.7M +107.78% | -813,739 -25.52% | -1.1M +48.45% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -8.2M -60.43% | -20.7M -27.32% | -28.5M -13.12% | -32.8M +33.61% | |
Net Income from Continuing Operations Applicable to Common | -8.6M -61.63% | -22.4M -21.39% | -28.5M -13.12% | -32.8M +33.61% | |
Basic EPS and Net Income | -0.13 -65.79% | -0.38 -40.62% | -0.64 -14.67% | -0.75 +31.58% | |
Diluted EPS and Net Income | -0.13 -65.79% | -0.38 -40.62% | -0.64 -14.67% | -0.75 +31.58% | |
Basic Weighted Average Shares | 62.2M +14.32% | 54.4M +21.90% | 44.7M +2.49% | 43.6M +0.49% | |
Diluted Weighted Average Shares | 62.2M +14.32% | 54.4M +21.90% | 44.7M +2.49% | 43.6M +0.49% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 6.2M +90.52% | 3.3M -76.79% | 14.1M -36.19% | 22.1M -57.53% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 6.2M +90.52% | 3.3M -76.79% | 14.1M -36.19% | 22.1M -57.53% | |
Total Current Assets | 20.6M -4.49% | 21.6M -15.95% | 25.7M -23.87% | 33.8M -47.50% | |
Accumulated Depreciation | 5.1M +21.80% | 4.2M +39.16% | 3.0M +60.07% | 1.9M -60.16% | |
Property and Plant and Equipment and Net | 7.8M -13.10% | 9.0M -10.48% | 10.1M -6.39% | 10.7M +108.57% | |
Total Long-Term Assets | 53,000 -98.59% | 3.8M -4.75% | 4.0M -10.79% | 4.4M -10.51% | |
Total Assets | 44.2M -6.73% | 47.4M -11.06% | 53.3M -15.77% | 63.2M -29.37% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 2.5M 0.00% | 2.5M N/A | N/A N/A | |
Total Current Liabilities | 9.7M -1.17% | 9.8M -32.46% | 14.5M +49.73% | 9.7M -29.04% | |
Total Long-Term Debt | 16.7M +19.08% | 14.0M +450.42% | 2.5M -49.14% | 5.0M +1,233.33% | |
Total Long-Term Liabilities | 28.6M +8.05% | 26.4M +71.25% | 15.4M -14.90% | 18.1M +36.91% | |
Total Liabilities | 38.3M +5.55% | 36.3M +20.94% | 30.0M +7.64% | 27.9M +3.40% | |
Retained Earnings | -312.2M +2.70% | -304.0M +7.61% | -282.5M +11.22% | -254.0M +14.83% | |
Total Stockholders Equity | 5.9M -46.85% | 11.1M -52.28% | 23.3M -34.20% | 35.4M -43.47% | |
Total Shares Outstanding | 62.8M +14.54% | 54.8M +1.09% | 54.2M +24.75% | 43.5M 0.00% | |
Cash Flow | |||||
Cash from Operating Activities | -12.4M -14.21% | -14.4M -33.37% | -21.7M -23.30% | -28.2M +101.59% | |
Capital Expenditures | 164,000 -42.32% | 284,343 -47.16% | 538,115 -91.16% | 6.1M +67.18% | |
Cash from Investing Activities | -415,000 -38.01% | -669,430 -28.50% | -936,236 -85.50% | -6.5M +50.79% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 9.3M -0.23% | 9.3M -35.54% | 14.5M +191.84% | 5.0M +593.46% | |
Financials Ratio | |||||
Gross Margin | 71.48% +1.26% | 70.59% +14.59% | 61.60% +3.07% | 59.77% -19.67% | |
Operating Margin | -39.79% -15.62% | -47.16% -45.07% | -85.86% -5.51% | -90.87% +72.46% | |
Return on Assets | -17.91% -56.51% | -41.18% -15.87% | -48.94% +13.92% | -42.96% +56.98% | |
Return on Equity | -96.39% -20.02% | -120.52% +23.98% | -97.21% +45.10% | -67.00% +93.41% | |
Revenue Growth | 4.13% +298.66% | -2.08% -143.38% | 4.79% +124.38% | -19.64% -472.63% | |
Current Ratio | 2.13 -3.36% | 2.20 +24.45% | 1.77 -49.15% | 3.48 -26.01% | |
Cash Ratio | 0.64 +92.75% | 0.33 -65.63% | 0.97 -57.38% | 2.28 -40.15% | |
Debt-to-Equity Ratio | N/A N/A | 1.49 +585.37% | 0.22 N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | 0.35 +267.69% | 0.09 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow